顺铂脂质体在肿瘤治疗中的研究进展
x
请在关注微信后,向客服人员索取文件
篇名: | 顺铂脂质体在肿瘤治疗中的研究进展 |
TITLE: | Research advances in cancer therapy of cisplatin liposome |
摘要: | 以顺铂类药物或其联合应用为基础的化疗是一类常见的肿瘤治疗方法,但出于顺铂的非特异性所导致的副作用、小分子药物的药代动力学特性较差、易产生耐药等原因,极大地限制了顺铂类药物作为一线抗肿瘤药物的临床应用。随着纳米载体技术的发展,脂质体凭借靶向、减毒、增效的优良特性,成为了递送顺铂类药物的理想载体。本文综述了国内外已进入临床研究的顺铂脂质体现状,包括L-NDDP、SPI-077®、Lipoplatin®、LiPlaCis、SLIT、ILC等,发现目前只有Lipoplatin®和ILC的发展势头良好。虽然顺铂脂质体在降低全身毒性、提高治疗效率等方面取得了一定进展,但在肿瘤靶向性和减少副作用方面仍有待进一步提升。未来可以通过共递送脂质体、刺激响应型脂质体和具有靶向功能的脂质体等制剂技术,开发出更加低毒、高效的顺铂脂质体。 |
ABSTRACT: | Chemotherapy based on cisplatin or its combination therapy is a common cancer treatment method. However, the non-specific side effects of cisplatin, poor pharmacokinetic properties of small molecule drugs, and susceptibility to drug resistance greatly limit the clinical application of cisplatin as first-line anti-tumor drug. With the development of nanocarrier technology, liposomes have become an ideal carrier for delivering cisplatin drugs due to their excellent properties of targeting, reducing toxicity, and enhancing efficacy. This paper reviews the status of cisplatin liposome both domestically and internationally which have entered clinical trials, including L-NDDP,SPI-077®, Lipoplatin®,LiPlaCis,SLIT and ILC, etc. Currently, only Lipoplatin® and ILC are showing good potential in cancer therapy. Although cisplatin liposome has made some progress in reducing systemic toxicity and improving treatment efficiency in clinical research, there is still potential for further improvement in tumor targeting and reducing side effects. In the future, more low-toxicity and efficient cisplatin liposomes can be developed through formulation technologies such as co-delivery liposome, stimuli-responsive liposome and targeting liposome. |
期刊: | 2025年第36卷第03期 |
作者: | 赵玮璇;卢雪;赵瑞林;张艳梅;杨晔;曹德英 |
AUTHORS: | ZHAO Weixuan,LU Xue,ZHAO Ruilin,ZHANG Yanmei,YANG Ye,CAO Deying |
关键字: | 顺铂;脂质体;肿瘤;共递送脂质体;刺激响应型脂质体;具有靶向功能的脂质体 |
KEYWORDS: | cisplatin; liposome; tumor; co-delivery liposome; stimuli-responsive liposome; targeting liposome |
阅读数: | 6 次 |
本月下载数: | 0 次 |
* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!